Nisa Investment Advisors
CLDX icon

Nisa Investment Advisors’s Celldex Therapeutics CLDX Stock Holding History

Nisa Investment Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$83.5K Buy
2,245
+1,305
+139% +$42.2K ﹤0.01% 1632
2026
Q1 		$29.8K Buy
940
+35
+4% +$954 ﹤0.01% 1872
2025
Q4 		$24.6K Sell
905
-490
-35% -$12.9K ﹤0.01% 1865
2025
Q3 		$36.1K Buy
1,395
+1
+0.1% +$23 ﹤0.01% 1728
2025
Q2 		$28.4K Buy
1,394
+881
+172% +$17.1K ﹤0.01% 1776
2025
Q1 		$9.31K Sell
513
-31
-6% -$693 ﹤0.01% 2114
2024
Q4 		$13.7K Sell
544
-138
-20% -$3.75K ﹤0.01% 2049
2024
Q3 		$23.2K Buy
682
+35
+5% +$1.33K ﹤0.01% 1867
2024
Q2 		$23.9K Sell
647
-120,926
-99% -$4.56M ﹤0.01% 1883
2024
Q1 		$5.1M Buy
121,573
+121,043
+22,838% +$4.97M 0.03% 432
2023
Q4 		$21K Sell
530
-710
-57% -$20.9K ﹤0.01% 1866
2023
Q3 		$34.1K Sell
1,240
-14
-1% -$439 ﹤0.01% 1844
2023
Q2 		$42.5K Buy
1,254
+230
+22% +$7.75K ﹤0.01% 1801
2023
Q1 		$37K Hold
1,024
– – ﹤0.01% 1808
2022
Q4 		$46K Hold
1,024
– – ﹤0.01% 1801
2022
Q3 		$36K Buy
1,024
+534
+109% +$16.4K ﹤0.01% 1861
2022
Q2 		$13K Sell
490
-900
-65% -$26.1K ﹤0.01% 2143
2022
Q1 		$47K Sell
1,390
-822
-37% -$26.3K ﹤0.01% 1862
2021
Q4 		$69K Sell
2,212
-588
-21% -$25.6K ﹤0.01% 1634
2021
Q3 		$151K Buy
+2,800
New +$131K ﹤0.01% 1524
2016
Q2 		– Sell
-80
Closed -$5K – 1863
2016
Q1 		$5K Sell
80
-1,647
-95% -$185K ﹤0.01% 1839
2015
Q4 		$406K Hold
1,727
– – 0.01% 1015
2015
Q3 		$273K Hold
1,727
– – ﹤0.01% 1131
2015
Q2 		$653K Hold
1,727
– – 0.01% 930
2015
Q1 		$722K Buy
1,727
+80
+5% +$28.6K 0.01% 913
2014
Q4 		$451K Hold
1,647
– – 0.01% 1040
2014
Q3 		$320K Buy
+1,647
New +$359K ﹤0.01% 1132

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nisa Investment Advisors's CLDX Position: Q2 2026 in Review

Nisa Investment Advisors increased its Celldex Therapeutics (CLDX) stake by 139% in Q2 2026, buying an estimated $42.2K and bringing the position to 2,245 shares worth $83.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1632.

Nisa Investment Advisors first reported a position in CLDX in Q3 2014 and has held it in 27 quarters since. The position peaked at $5.1M in Q1 2024. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Nisa Investment Advisors held 2,245 shares of Celldex Therapeutics worth $83.5K as of Q2 2026.
  • Nisa Investment Advisors bought 1,305 Celldex Therapeutics shares in Q2 2026, an estimated $42.2K.
  • Celldex Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #1632 holding.
  • Nisa Investment Advisors first reported a position in Celldex Therapeutics in Q3 2014 and has held it in 27 quarters since.
  • Nisa Investment Advisors's Celldex Therapeutics position peaked at $5.1M in Q1 2024.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.